Drug-Receptor Interactions: Affinity, Efficacy, and Antagonism

Added:

Biased Agonism (Functional Selectivity)

While classical receptor theory models drug-receptor interactions using static parameters of affinity and intrinsic efficacy—assuming a drug stabilizes a single active receptor state to trigger a linear response—the paradigm of biased agonism (or functional selectivity) challenges this view. Biased agonism recognizes that receptors are dynamic proteins capable of adopting multiple distinct active conformations. Consequently, a ligand can selectively stabilize a specific conformation, preferentially activating one downstream signaling pathway (such as G-protein signaling) while avoiding or blocking another (such as beta-arrestin recruitment) at the exact same receptor. This multidimensional model of efficacy demonstrates that a drug does not possess a single, fixed efficacy value. Instead, its efficacy is pathway-dependent, meaning a drug can act as an agonist for one cellular response and simultaneously as an antagonist for another, fundamentally complicating traditional concentration-response and classification models.

Basic cellular biology, specifically the structure and function of cell membranes and membrane-bound receptor proteins.
Fundamental biochemical principles, including the types of chemical bonds (such as covalent, ionic, and hydrogen bonds) that facilitate ligand-protein interactions.
The concept of endogenous signaling, including how hormones and neurotransmitters naturally bind to targets to elicit physiological responses.
Basic graphing skills, specifically how to interpret Cartesian and semi-logarithmic plots, which are essential for understanding concentration-response curves.
Intracellular signal transduction cascades, exploring how receptor activation leads to downstream cellular responses (e.g., G-proteins, second messengers like cAMP).
Advanced pharmacodynamics concepts, such as biased agonism (functional selectivity), allosteric modulation, and the concept of spare receptors.
The mechanisms of receptor regulation, including receptor desensitization (downregulation) and hypersensitivity (upregulation) over time.
Clinical pharmacodynamics parameters, such as calculating the therapeutic index (safety window) using effective dose (ED50) and toxic dose (TD50) curves.
Pharmacokinetics, which studies how the body processes a drug (Absorption, Distribution, Metabolism, and Excretion) to complement these pharmacodynamic principles.
23K views571likes52:37@EKGScienceOriginal Release: 2023-08-23

Drug-receptor interactions involve two key parameters: affinity (the strength of drug binding to receptors, measured by KD) and efficacy (the ability to activate receptors after binding). Agonists possess both affinity and efficacy to produce biological responses, while antagonists have affinity but zero efficacy. Concentration-response curves (CRCs) plot drug concentration against effect, revealing Emax (maximum response) and EC50 (concentration for 50% response). Potency relates to EC50—lower EC50 means higher potency. Antagonism includes competitive (reversible/surmountable) and non-competitive (irreversible/insurmountable) types, which can be distinguished by their effects on CRCs: competitive causes parallel rightward shifts without reducing Emax, while non-competitive reduces Emax regardless of agonist concentration.